Answers are grounded in this paper and cite their sources.
This systematic review and meta-analysis quantitatively evaluates the preclinical efficacy of brown marine algae (Sargassum spp.) in managing diabetes mellitus and diabetic dyslipidemia across in vivo animal models. While Sargassum extracts rich in phlorotannins, fucoidans, and fucoxanthin demonstrate promising antidiabetic properties, existing literature remains fragmented and methodologically inconsistent. To address these gaps, this project unifies all metabolic outcomes into standardized biological units (mg/dL for glucose and lipid profiles) and applies rigorous dispersion transformations (SD = SEM times sqrt{n}) to prevent variance distortion. Utilizing random-effects meta-analytic models across peer-reviewed and grey literature (e.g., conference proceedings), the study aims to establish pooled effect sizes for fasting blood glucose and lipid panel parameters (Total Cholesterol, Triglycerides, HDL-C, LDL-C), evaluate secondary safety markers (hepatic/renal safety and oxidative stress), and identify efficacy moderators (extraction solvent, dose, and treatment duration) to inform future translational research and nutraceutical development.
No takes yet. Share an insight, caveat, or question.
Muruganantham et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: